NASDAQ · GELS
Healthcare · Drug Manufacturers - Specialty & Generic
$0.56
Down-$0.03 (-5.53%)
Updated Aug 24, 2026, 8:29 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
GELS closed at $0.56 after 20 trading sessions, down 14.86% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $0.589 | $0.589 | $0.5366 | $0.5628 | 21.04K |
| Aug 20, 2026 | $0.5601 | $0.5797 | $0.53 | $0.5576 | 29.65K |
| Aug 19, 2026 | $0.5301 | $0.5899 | $0.5301 | $0.5559 | 11.26K |
| Aug 18, 2026 | $0.53 | $0.5849 | $0.53 | $0.5315 | 27.57K |
| Aug 17, 2026 | $0.6015 | $0.6172 | $0.56 | $0.5641 | 35K |
| Aug 14, 2026 | $0.612 | $0.63 | $0.58 | $0.58 | 26.64K |
| Aug 13, 2026 | $0.5911 | $0.612 | $0.5701 | $0.581 | 11.12K |
| Aug 12, 2026 | $0.5693 | $0.6054 | $0.551 | $0.5706 | 20.38K |
| Aug 11, 2026 | $0.5758 | $0.6013 | $0.5702 | $0.5705 | 12.98K |
| Aug 10, 2026 | $0.57 | $0.6052 | $0.5581 | $0.5846 | 33.85K |
| Aug 7, 2026 | $0.5832 | $0.5832 | $0.5459 | $0.5579 | 11.43K |
| Aug 6, 2026 | $0.58 | $0.6401 | $0.5702 | $0.574 | 55.85K |
| Aug 5, 2026 | $0.5401 | $0.5851 | $0.5401 | $0.5641 | 53.79K |
| Aug 4, 2026 | $0.56 | $0.6055 | $0.5336 | $0.5336 | 56.69K |
| Aug 3, 2026 | $0.52 | $0.569 | $0.486 | $0.54 | 80.23K |
| Jul 31, 2026 | $0.5527 | $0.6381 | $0.5201 | $0.5201 | 25.37K |
| Jul 30, 2026 | $0.58 | $0.6198 | $0.551 | $0.551 | 77.9K |
| Jul 29, 2026 | $0.5959 | $0.5965 | $0.55 | $0.5757 | 68.01K |
| Jul 28, 2026 | $0.63 | $0.6449 | $0.57 | $0.587 | 107.25K |
| Jul 27, 2026 | $0.6945 | $0.70 | $0.66 | $0.661 | 48.76K |
The latest Smart Investors Daily articles mentioning GELS.
GELS research
Company profile and research snapshot.
Gelteq Ltd is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, preserving the simplicity, accessibility, and efficacy of oral delivery. Its principal products are edible gels and their application in gel-based dosage forms across pets, sports, pharmaceutical, over-the-counter, and nutraceutical categories, leveraging its patent pending multiple ingredient dosage forms. The company develops and tests gel-based delivery systems for humans and pets and focuses on out-licensing its technology to companies to create products that can be manufactured and sold, while continuing to manufacture existing products under license on a white label basis.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Jun 17, 2026
Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a biotechnology company developing a proprietary gel-based delivery platform for pharmaceutical, animal health and consumer health applications, today provided a
ChartMill · Jun 15, 2026
Here are the top movers in Monday's session, showcasing the stocks with significant price changes.
Benzinga · Jun 12, 2026
Micro-cap biotechnology stock Gelteq (GELS) faces erratic price swings, pulling back after a 200% spike. Stock down 33%.
Benzinga · Feb 11, 2026
Healthy Extracts will serve as the primary manufacturer, commercial seller, and distribution partner for this range of products. Gelteq will provide the required technical transfer to enable manufacturing whilst
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GELS.
No results
No recent SID articles mention GELS.
